The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity

Stuart G. Marcus, Donna Perry-Lalley, James J. Mulé, Steven A. Rosenberg, James C. Yang

Research output: Contribution to journalArticle

Abstract

Tumor-infiltrating lymphocytes (TIL) are cytotoxic T cells isolated from solid tumors and expanded in vitro in recombinant interleukin-2 (rIL-2). TIL have antitumor effects in murine models and in some patients with melanoma. In an effort to generate murine TIL with enhanced in vivo therapeutic efficacy, viable tumor cells were coinjected with a collagen matrix plus recombinant human IL-6 (rIL-6) subcutaneously into syngeneic mice to achieve sustained local concentrations of rIL-6 at the tumor site from which TIL were derived. In five separate experiments, single cell suspensions of tumors were admixed with either (a) Hanks' balanced salt solution (HBSS), (b) 2% (20 mg/ml) collagen matrix only, (c) 250 µg rIL-6 only, or (d) 250 µg rIL-6 in a 2% collagen matrix (prolonged release) before subcutaneous inoculation. These tumors were subsequently resected and TIL were isolated and expanded in vitro. TIL generated from tumors admixed with matrix plus rIL-6 were significantly more effective than TIL expanded from tumors admixed with HBSS (four of five experiments), TIL from tumors admixed with matrix only (five of five experiments), and TIL from tumors admixed with rIL-6 only (three of four experiments) in an established tumor treatment model. In no experiment was any other TIL culture superior to TIL grown from tumors augmented with collagen matrix plus rIL-6. These results suggest that strategies designed to increase the local concentrations of cytokines at tumor sites may lead to the generation of more potent TIL for clinical administration.

Original languageEnglish (US)
Pages (from-to)105-112
Number of pages8
JournalJournal of Immunotherapy
Volume15
Issue number2
StatePublished - 1994
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Interleukin-6
Neoplasms
Collagen
Interleukin-2
Melanoma
Suspensions

Keywords

  • Adoptive immunotherapy
  • Collagen matrix
  • Cytokine
  • Interleukin- 6
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Marcus, S. G., Perry-Lalley, D., Mulé, J. J., Rosenberg, S. A., & Yang, J. C. (1994). The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. Journal of Immunotherapy, 15(2), 105-112.

The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. / Marcus, Stuart G.; Perry-Lalley, Donna; Mulé, James J.; Rosenberg, Steven A.; Yang, James C.

In: Journal of Immunotherapy, Vol. 15, No. 2, 1994, p. 105-112.

Research output: Contribution to journalArticle

Marcus, SG, Perry-Lalley, D, Mulé, JJ, Rosenberg, SA & Yang, JC 1994, 'The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity', Journal of Immunotherapy, vol. 15, no. 2, pp. 105-112.
Marcus, Stuart G. ; Perry-Lalley, Donna ; Mulé, James J. ; Rosenberg, Steven A. ; Yang, James C. / The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. In: Journal of Immunotherapy. 1994 ; Vol. 15, No. 2. pp. 105-112.
@article{f20b975fb14a4fc99a7396e3f3e3ad81,
title = "The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity",
abstract = "Tumor-infiltrating lymphocytes (TIL) are cytotoxic T cells isolated from solid tumors and expanded in vitro in recombinant interleukin-2 (rIL-2). TIL have antitumor effects in murine models and in some patients with melanoma. In an effort to generate murine TIL with enhanced in vivo therapeutic efficacy, viable tumor cells were coinjected with a collagen matrix plus recombinant human IL-6 (rIL-6) subcutaneously into syngeneic mice to achieve sustained local concentrations of rIL-6 at the tumor site from which TIL were derived. In five separate experiments, single cell suspensions of tumors were admixed with either (a) Hanks' balanced salt solution (HBSS), (b) 2{\%} (20 mg/ml) collagen matrix only, (c) 250 µg rIL-6 only, or (d) 250 µg rIL-6 in a 2{\%} collagen matrix (prolonged release) before subcutaneous inoculation. These tumors were subsequently resected and TIL were isolated and expanded in vitro. TIL generated from tumors admixed with matrix plus rIL-6 were significantly more effective than TIL expanded from tumors admixed with HBSS (four of five experiments), TIL from tumors admixed with matrix only (five of five experiments), and TIL from tumors admixed with rIL-6 only (three of four experiments) in an established tumor treatment model. In no experiment was any other TIL culture superior to TIL grown from tumors augmented with collagen matrix plus rIL-6. These results suggest that strategies designed to increase the local concentrations of cytokines at tumor sites may lead to the generation of more potent TIL for clinical administration.",
keywords = "Adoptive immunotherapy, Collagen matrix, Cytokine, Interleukin- 6, Tumor-infiltrating lymphocytes",
author = "Marcus, {Stuart G.} and Donna Perry-Lalley and Mul{\'e}, {James J.} and Rosenberg, {Steven A.} and Yang, {James C.}",
year = "1994",
language = "English (US)",
volume = "15",
pages = "105--112",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity

AU - Marcus, Stuart G.

AU - Perry-Lalley, Donna

AU - Mulé, James J.

AU - Rosenberg, Steven A.

AU - Yang, James C.

PY - 1994

Y1 - 1994

N2 - Tumor-infiltrating lymphocytes (TIL) are cytotoxic T cells isolated from solid tumors and expanded in vitro in recombinant interleukin-2 (rIL-2). TIL have antitumor effects in murine models and in some patients with melanoma. In an effort to generate murine TIL with enhanced in vivo therapeutic efficacy, viable tumor cells were coinjected with a collagen matrix plus recombinant human IL-6 (rIL-6) subcutaneously into syngeneic mice to achieve sustained local concentrations of rIL-6 at the tumor site from which TIL were derived. In five separate experiments, single cell suspensions of tumors were admixed with either (a) Hanks' balanced salt solution (HBSS), (b) 2% (20 mg/ml) collagen matrix only, (c) 250 µg rIL-6 only, or (d) 250 µg rIL-6 in a 2% collagen matrix (prolonged release) before subcutaneous inoculation. These tumors were subsequently resected and TIL were isolated and expanded in vitro. TIL generated from tumors admixed with matrix plus rIL-6 were significantly more effective than TIL expanded from tumors admixed with HBSS (four of five experiments), TIL from tumors admixed with matrix only (five of five experiments), and TIL from tumors admixed with rIL-6 only (three of four experiments) in an established tumor treatment model. In no experiment was any other TIL culture superior to TIL grown from tumors augmented with collagen matrix plus rIL-6. These results suggest that strategies designed to increase the local concentrations of cytokines at tumor sites may lead to the generation of more potent TIL for clinical administration.

AB - Tumor-infiltrating lymphocytes (TIL) are cytotoxic T cells isolated from solid tumors and expanded in vitro in recombinant interleukin-2 (rIL-2). TIL have antitumor effects in murine models and in some patients with melanoma. In an effort to generate murine TIL with enhanced in vivo therapeutic efficacy, viable tumor cells were coinjected with a collagen matrix plus recombinant human IL-6 (rIL-6) subcutaneously into syngeneic mice to achieve sustained local concentrations of rIL-6 at the tumor site from which TIL were derived. In five separate experiments, single cell suspensions of tumors were admixed with either (a) Hanks' balanced salt solution (HBSS), (b) 2% (20 mg/ml) collagen matrix only, (c) 250 µg rIL-6 only, or (d) 250 µg rIL-6 in a 2% collagen matrix (prolonged release) before subcutaneous inoculation. These tumors were subsequently resected and TIL were isolated and expanded in vitro. TIL generated from tumors admixed with matrix plus rIL-6 were significantly more effective than TIL expanded from tumors admixed with HBSS (four of five experiments), TIL from tumors admixed with matrix only (five of five experiments), and TIL from tumors admixed with rIL-6 only (three of four experiments) in an established tumor treatment model. In no experiment was any other TIL culture superior to TIL grown from tumors augmented with collagen matrix plus rIL-6. These results suggest that strategies designed to increase the local concentrations of cytokines at tumor sites may lead to the generation of more potent TIL for clinical administration.

KW - Adoptive immunotherapy

KW - Collagen matrix

KW - Cytokine

KW - Interleukin- 6

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=0028012754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028012754&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 105

EP - 112

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 2

ER -